Primary malignant melanoma of the esophagus, treated with immunotherapy: a case report

Immunotherapy. 2018 Aug;10(10):831-835. doi: 10.2217/imt-2018-0011.

Abstract

Primary malignant melanoma of the esophagus is rare, accounting for less than 0.1-0.2% of all esophageal malignancies. It is associated with a poor outcome due to late detection and high metastatic potential. Here, we report a case of esophageal cancer, which was initially diagnosed as an adenocarcinoma and finally was confirmed as a primary malignant melanoma. This 75-year-old Caucasian male had a history of dysphagia and recent lingering abdominal pain. First biopsy showed a poorly-differentiated adenocarcinoma. He was then treated with neoadjuvant radiochemotherapy. Biopsies were repeated because of an incomplete tumor response, evaluated by endoscopic and imaging studies. The final diagnosis was a malignant melanoma. The patient has been treated with immune-checkpoint inhibitor, nivolumab, an anti-PD1 antibody.

Keywords: esophagus; immunotherapy; melanoma; nivolumab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / pathology
  • Humans
  • Immunotherapy / methods
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Nivolumab / therapeutic use*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab